Genmab — Maj 2016
-
Nu har jeg haft tid til at læse Novods Genmab note fra i morges igen. En har specielt fremhæver er "very importantly, als can be seen from the PFS Kaplan Mayer curve below, we also see that after 15 months, the Darzalex/Rev/Dex curve completely flattens, i.e. patients to not progress, which is a very promissing sign in our view and could indicate the immonu-oncology properties of Darzalex."
-
Jeg kan ikke vise kurven, men jeg tror teksten siger alt. Empliciti/Rev/Dex kurven fortsætter bare i hullet!
-
I forhold til Darzalex/Rev/Dex.
-
Begge bliver målt mod Rev/Dex. Men Darzalex/Rev/Dex da flader kurven totalt efter 15 måneder. Dvs sygdommen udvikler sig ikke yderligere i negativ retning. Det gør den fortsat i Empliciti armen med Rev/Dex.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind